1. Bonomi, P., Kim, K., Chang, A. & Johnson, D. (1996). Phase III trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol 15: 1145 (Abstract)
2. Bonomi, P., Kyungmann, K., Kusler, J. & Johnson, D. (1997). Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. Oncology 11: 9–10.
3. Canadian Coordinating Office for Health Technology, Assessment (1997). The Use of G-CSF in the Prevention of Febrile Neutropenia. Canadian Coordinating Office for Health Technology Assessment (CCOHTA): Ottawa
4. Chang, A. Y., Kim, K., Glick, J., Anderson, T., Karp, D. & Johnson, D. (1993). Phase II study of Taxol, Merbarone, and Piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85: 388–394.
5. Detsky, A. & Naglie, I. (1990). A clinician’s guide to cost-effectiveness analysis. Ann Int Med 113: 147–154.